OIL

5.71%

16.5¢ optiscan imaging limited

Ann: Appendix 4G and Corporate Governance Statement, page-4

First 4 Last

Share
Profile

Follow
chand

3,664 Posts.

858

30/08/19

16:32

Post #: 40248919
Share

Originally posted by Morrison6 ↑

Did anyone see a mention of when they expect to break even? I didn't see it in there but could have missed it. If there is no expectation of achieving break even in the year ahead then it means more capital raisings/further dilution. It would be great to see the beginnings of growth of sales. I appreciate that they may not want to make forward looking statements that then sees them with egg on their face but must be hard for holders to maintain hope when profitability still seems to be more than 12 months away.

It would be great to see a little table showing how many hospitals will eventually need to own one of the whizz bang new convivo equipped machines and some data on how quickly they think those hospitals will change over from their older ways of doing so. A little table that shows how much dough optiscan can expect to eventually receive from the collaboration etc. if 'x' hospitals buy one etc. Just a range or a target would be great. Put in lots of disclaimers about how hard it is to get those projections accurate but maybe some info about how long other major techological advances of a comparable cost have taken to be adopted by 'x' % of hospitals and then by 'y' % of hospitals.

Ok yes I may be speaking like an ignoramus etc and lets let the managers of the business do their thing etc but surely the OWNERS of the business are entitled to a little peak at the blue sky rather than just saying 'there is blue sky holders'.

Note - not a holder at present but a keen follower and would like to hold again one day.

Expand

What an unmitigated disaster this company has been turned into by this BOD. No one wants to buy Five2 and no hints about Convivo sales.
The only one laughing all the way to the bank is Executive Chairman - seriously more than $400K per year when the company is bleeding badly and will require more SH capital infusion to survive it seems.

OIL Price at posting: 4.3¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 1 more message in this thread...

First 4 Last

Add OIL (ASX) to my watchlist

(20min delay)
Last 16.5¢		Change -0.010(5.71%)		Mkt cap ! $137.8M

Open	High	Low	Value	Volume
17.5¢	17.5¢	16.5¢	$16.50K	97.44K

Buyers (Bids)

No.	Vol.	Price($)
5	168328	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	25000	1

View Market Depth

No.	Vol.	Price($)
3	150000	0.165
5	266250	0.160
2	450000	0.155
4	54268	0.150
1	30070	0.145

Price($)	Vol.	No.
0.190	39837	3
0.195	121821	2
0.200	542000	3
0.205	161553	3
0.210	9440	2

Last trade - 11.27am 04/10/2024 (20 minute delay)

OIL (ASX) Chart

Ann: Appendix 4G and Corporate Governance Statement, page-4

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 4G and Corporate Governance Statement, page-4

Top Stories

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News